First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014

Clinical Cancer Research

Volumn 21, Issue 15, 2015, Pages 3412-3419

  Basu, Bristi ^a   Dean, Emma ^b   Puglisi, Martina ^a   Greystoke, Alastair ^b   Ong, Michael ^a   Burke, Wendy ^c   Cavallin, Maria ^c   Bigley, Graham ^c   Womack, Christopher ^c   Harrington, Elizabeth A ^c   Green, Stephen ^c   Oelmann, Elisabeth ^c   De Bono, Johann S ^a   Ranson, Malcolm ^b   Banerji, Udai ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN S6; VISTUSERTIB; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BIOPSY TECHNIQUE; BREAST CANCER; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERBB2 GENE; FATIGUE; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; HUMAN; HYPOKALEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOWER RESPIRATORY TRACT INFECTION; MALE; MASS SPECTROMETRY; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PANCREAS CANCER; PDGFR GENE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; VOMITING; XEROSTOMIA; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; MULTIPROTEIN COMPLEXES; NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84937815039     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2422     Document Type: Article

References (26)

1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
2. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
3. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009; 122: 3589-94.
4. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol 2013; 15: 1340-50.
5. Goral S, Helderman JH. The evolution and future of immunosuppression in renal transplantation. Semin Nephrol 1997; 17: 364-72.
6. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
7. Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012; 23: 1943-53.
8. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
9. Baselga J, Campone M, Piccart M, Burris HAIII, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-9.
10. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. NEngl J Med 2011; 364: 514-23.
11. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40.
12. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2isrequired for signalingtoAkt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006; 11: 859-71.
13. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-10.
14. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
15. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23: 1212-6.
16. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 2013; 27: 586-94.
17. Tabernero J, Cervantes A, Gordon M, Chiorean E, Burris H, Macarulla T, et al. A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. Cancer Res 2012; 72: Abstract CT-02.
18. Capelan M, Kumar P, Tolcher A, Zivi A, Desai M, Papadopoulos K, et al. A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: preliminary results. Mol Cancer Ther 2013; 12: Abstract C173.
19. Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 2011; 10: 1394-406.
20. Tan D, Dumez H, Olmos D, Sandhu S, Hoeben A, Stephens A, et al. First-inhuman phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J Clin Oncol 2010; 28: Abstract 3006.
21. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-98.
22. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012; 107: 1093-9.
23. O'Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-95.
24. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2weeks to patients with advanced cancer. Clin Cancer Res 2006; 12: 5755-63.
25. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009; 15: 1428-34.
26. Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target ofrapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31: 2485-92.